Monopar Therapeutics has surged 30% in a single week — yet short interest remains near 24% of float and the lending pool is close to fully squeezed, making the tension between bulls and bears unusually charged.
The borrow market tells the most interesting part of this week's story. Availability has been deeply crimped for most of June, dropping as low as 2.5% on June 16 before a brief loosening mid-month and then tightening again to just 10.7% by June 25. At that level, roughly only one share remains available to borrow for every nine already lent out — a structurally constrained environment for anyone trying to build fresh short exposure. Cost to borrow, at 3.2%, has nudged higher through the week but remains far from punishing levels, so the real constraint isn't price — it's supply. Short interest itself has actually eased modestly, falling about 3.6% over the past week to 23.9% of the free float. That's still a heavily shorted position by any measure, but the direction of travel suggests some shorts are quietly covering into the rally rather than pressing. The ORTEX short score of 81.4 places MNPR near the extreme end of the short-pressure spectrum, while the utilization rank and days-to-cover rank both sit in the bottom 3rd percentile of the universe — confirming the borrow market leaves little room for new short construction.
The Street remains constructive, if not freshly so. Nine analysts carry Buy-equivalent ratings, with a consensus mean target of around $113 — sitting roughly 29% above Friday's close of $87.68, so there is nominal upside implied by the coverage. However, the most recent analyst actions on record are from late March, with Chardan Capital and BTIG both simply reiterating existing Buy ratings and targets of $100 and $104 respectively. Morgan Stanley's January initiation at Overweight with a $115 target is the highest on the board. The analyst data carries a staleness flag of 50 days — no fresh moves have emerged to either validate or challenge the recent price run. Bulls point to the Wilson disease candidate's clinical data and the radiopharmaceutical pipeline; bears flag AstraZeneca's decision to abandon its own Wilson disease program, which clouds sentiment around the category, alongside the perennial funding risk facing a pre-revenue micro-cap. The price-to-book multiple has expanded sharply — up 1.7x over the past week alone to 6.1x — reflecting how fast sentiment can re-rate a name this small when momentum turns.
Institutional ownership adds an interesting wrinkle. Janus Henderson holds nearly 20% of shares, RA Capital almost 10%, and AstraZeneca itself still appears on the register with a 7.8% stake as of December 2025 — a notable position given the bear case around that company's strategic retreat from the Wilson disease space. Deerfield Management added 153,000 shares in the latest reported quarter, and Polar Capital added 121,000, while Adage Capital trimmed 290,000. The net institutional picture is mixed rather than directionally clear. Insider activity is low in both scale and significance — the most recent trades were small award-related sells by the CEO and COO in March.
Earnings are not due until August 14, giving the current positioning some room to evolve before the next binary event. With availability this tight and short interest still near 24% of float, any news — positive or negative — from the Wilson disease or radiopharmaceutical programs will collide with a lending market that has almost no slack in it.
See the live data behind this article on ORTEX.
Open MNPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
